Sumitomo Chemical India Limited — Investor Meet, 04-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sumitomo Chemical India achieved record FY26 profitability: PAT of INR 543 Cr (+7% YoY) on INR 3,238 Cr revenue (+3%), delivering a 16.8% net margin. Q4 PAT rose 12% to INR 111 Cr. Domestic sales grew 4%, boosted by branded products (81% share) and new herbicides like Lentigo. India is now a global hub for early-stage molecule trials. Animal nutrition distribution restarts, and a new royalty deal for specific products aims to enhance margins. Management is cautiously optimistic for FY27, actively managing cost pressures and external risks like monsoon, confident in sustainable margins. Dr. Suresh Ramachandran takes over as MD from Sep 1, 2026.